Home
report store
von willebrand disease vwd market insight

Von Willebrand disease (VWD) - Market Insights, Epidemiology, and Market Forecast-2030

Published Date : 2021

Pages : 200

Region : United States, Japan, EU4 & UK

Summary
TOC Table of Content
LOT
Companies
- Sample Request

von willebrand disease vwd market insight

elveInsight’s ‘Von Willebrand Disease-Market Insights, Epidemiology, and Market Forecast–2030’ report delivers an in-depth understanding of the Von Willebrand Disease historical and forecasted epidemiology as well as the Von Willebrand Disease market trends in the United States.

The Von Willebrand Disease market report provides current treatment practices and market share of the individual therapies, current and forecasted US Von Willebrand Disease market size from 2021 to 2030. The Report also covers current Von Willebrand Disease treatment practice, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

The United States

Study Period: 2018–2030

Von Willebrand Disease Understanding and Treatment Algorithm

The DelveInsight’s Von Willebrand Disease (VWD) market report gives a thorough understanding of the Von Willebrand Disease (VWD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Von Willebrand Disease (VWD) Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Von Willebrand Disease (VWD).

Von Willebrand Disease (VWD) Treatment

It covers the details of conventional and current medical therapies available in the Von Willebrand Disease (VWD) market for the treatment of the condition. It also provides Von Willebrand Disease (VWD) treatment algorithms and guidelines in the United States, Europe, and Japan.

Von Willebrand Disease Epidemiology

The Von Willebrand Disease (VWD) epidemiology section provides insights about the historical and current Von Willebrand Disease (VWD) patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Von Willebrand Disease (VWD) market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Von Willebrand Disease (VWD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Von Willebrand Disease (VWD) Epidemiology

The epidemiology segment also provides the Von Willebrand Disease (VWD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Von Willebrand Disease Drug Chapters

The drug chapter segment of the Von Willebrand Disease (VWD) report encloses the detailed analysis of Von Willebrand Disease (VWD) marketed drugs and late-stage (Phase-III and Phase-II) Von Willebrand Disease (VWD) pipeline drugs. It also helps to understand the Von Willebrand Disease (VWD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Von Willebrand Disease (VWD) Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Von Willebrand Disease (VWD) treatment.

Von Willebrand Disease (VWD) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Von Willebrand Disease (VWD) treatment.

Von Willebrand Disease Market Outlook

The Von Willebrand Disease (VWD) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Von Willebrand Disease (VWD) market trends by analyzing the impact of current Von Willebrand Disease (VWD) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Von Willebrand Disease (VWD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Von Willebrand Disease (VWD) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Von Willebrand Disease (VWD) market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the Von Willebrand Disease (VWD) market in 7MM.

The United States Market Outlook

This section provides the total Von Willebrand Disease (VWD) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Von Willebrand Disease (VWD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Von Willebrand Disease (VWD) market size and market size by therapies in Japan is also mentioned.

Von Willebrand Disease Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Von Willebrand Disease market. The analysis covers the Von Willebrand Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Reimbursement Scenario in Von Willebrand Disease

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive market Intelligence analysis of the Von Willebrand Disease market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

The report covers the descriptive overview of Von Willebrand Disease, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
Comprehensive insight has been provided into the Von Willebrand Disease epidemiology and treatment.
A detailed review of the Von Willebrand Disease market; historical and forecasted is included in the report, covering the US drug outreach.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the US Von Willebrand Disease market.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Von Willebrand Disease R&D.
Our in-depth analysis will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Von Willebrand Disease Report Insights

Patient Population
Therapeutic Approaches
Pipeline Analysis
Von Willebrand Disease Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Von Willebrand Disease Report Key Strengths

10 Years Forecast
US Coverage
Von Willebrand Disease Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Von Willebrand Disease Report Assessment

Current Treatment Practices
Unmet Needs
Market Attractiveness
Market Drivers and Barriers

Key Questions

Market Insights:

What was the Von Willebrand Disease market share (%) distribution in 2018 and how it would look like in 2030?
What would be the Von Willebrand Disease total market size as well as market size by therapies in the US during the forecast period (2021–2030)?
What are the key findings pertaining to the US market?
At what CAGR, the Von Willebrand Disease market is expected to grow at the US level during the forecast period (2021–2030)?
What would be the Von Willebrand Disease market outlook in the US during the forecast period (2021–2030)?
What would be the Von Willebrand Disease market growth till 2030 and what will be the resultant market size in the year 2030?
How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What are the disease risk, burdens, and unmet needs of Von Willebrand Disease?
What is the historical Von Willebrand Disease patient pool in the United States?
What would be the forecasted patient pool of Von Willebrand Disease in the US?
What will be the growth opportunities in the US with respect to the patient population pertaining to Von Willebrand Disease?
At what CAGR the population is expected to grow in the US during the forecast period (2021–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

What are the current options for the treatment of Von Willebrand Disease along with the approved therapy?
What are the current treatment guidelines for the treatment of Von Willebrand Disease in the US?
What are the Von Willebrand Disease marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Von Willebrand Disease therapies?
What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
What are the key designations that have been granted for the emerging therapies for Von Willebrand Disease?
What are the US historical and forecasted market of Von Willebrand Disease?

Reasons to buy

The report will help in developing business strategies by understanding trends shaping and driving Von Willebrand Disease.
To understand the future market competition in the Von Willebrand Disease market and Insightful review of the key market drivers and barriers.
Organize sales and marketing efforts by identifying the best opportunities for Von Willebrand Disease in the US.
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
Organize sales and marketing efforts by identifying the best opportunities for the Von Willebrand Disease market.
To understand the future market competition in the Von Willebrand Disease market.

1. Key Insights

2. Report Introduction

3. Executive Summary of Von Willebrand Disease (VWD)

4. Disease Background and Overview: Von Willebrand Disease (VWD)

4.1. Introduction

4.2. Symptoms of Von Willebrand disease

4.3. Classification of Von Willebrand disease

4.4. Causes of Von Willebrand disease (VWD)

4.5. Clinical Manifestations of Von Willebrand disease (VWD)

4.6. Genetic Basis of Von Willebrand disease

4.7. Pathophysiology of Von Willebrand disease (VWD)

4.8. Diagnosis of Von Willebrand disease

4.9. Diagnostic Guidelines of Immune Thrombocytopenia

4.9.1. The Diagnosis, Evaluation, and Management of von Willebrand Disease from the National Heart Lung and Blood Institute, National Institutes of Health

4.9.2. The diagnosis of von Willebrand disease: a guideline from the UK Hemophilia Centre Doctor’s Organization

4.10. Treatment Algorithm, Current Treatment, and Medical Practices

4.10.1. 2012 Clinical Practice Guideline on the Evaluation and Management of von Willebrand Disease (VWD)

4.10.2. The Diagnosis, Evaluation, and Management of von Willebrand Disease from the National Heart Lung and Blood Institute, National Institutes of Health

4.10.3. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. Methodology of Epidemiology

5.3. United States

5.3.1. Assumptions and Rationale

5.3.2. Total Diagnosed Prevalent Population of Von Willebrand Disease in the United States

5.3.3. Gender-Specific Diagnosed Prevalent Population of Von Willebrand Disease in the United States

5.3.4. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in the United States

5.3.5. Type Specific Diagnosed Prevalent Population of Von Willebrand Disease in the United States

6. Marketed Therapies

6.1. Key Cross Competition

6.2. Vonvendi: Shire

6.2.1. Drug Description

6.2.2. Mechanism of Action

6.2.3. Regulatory Milestones

6.2.4. Advantages and Disadvantages

6.2.5. Clinical Development

6.2.6. Clinical Trials Information

6.2.7. Safety and Efficacy

6.2.8. Product Profile

6.3. Humate-P/Haemate P: CSL Behring

6.3.1. Drug Description

6.3.2. Mechanism of Action

6.3.3. Regulatory Milestones

6.3.4. Advantages and Disadvantages

6.3.5. Safety and Efficacy

6.3.6. Product Profile

6.4. Wilate: Octapharma

6.4.1. Drug Description

6.4.2. Mechanism of Action

6.4.3. Regulatory Milestones

6.4.4. Advantages and Disadvantages

6.4.5. Clinical Development

6.4.6. Clinical Trials Information

6.4.7. Safety and Efficacy

6.4.8. Product Profile

6.5. Desmopressin: Ferring Pharmaceuticals

6.5.1. Drug Description

6.5.2. Mechanism of Action

6.5.3. Regulatory Milestones

6.5.4. Advantages and Disadvantages

6.5.5. Product Profile

6.6. Alphanate: Grifols Biological Inc.

6.6.1. Drug Description

6.6.2. Mechanism of Action

6.6.3. Regulatory Milestones

6.6.4. Advantages and Disadvantages

6.6.5. Safety and Efficacy

6.6.6. Product Profile

7. Von Willebrand Disease: US Market Analysis

7.1. Key Findings

7.2. Methodology of Von Willebrand Disease Market

7.3. The United States Market Outlook

7.4. United States Market Size

7.4.1. Total Market size of Von Willebrand Disease

7.4.2. Market Size by Therapies

8. Market Drivers

9. Market Barriers

10. Unmet Needs

11. Appendix

11.1. Report Methodology

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

List of Tables:

List of Table

Table 1: Summary of Von Willebrand Disease (VWD), Market and Epidemiology (2018–2030)

Table 2: Classification of von Willebrand disease

Table 3: Sub-Classification of von Willebrand disease Type 2A

Table 4: Level of Evidence

Table 5: Treatment of von Willebrand Disease

Table 6: Indications for Replacement Therapy in VWD

Table 7: Diagnosed Prevalent Cases of Von Willebrand Disease in the United States (2018–2030)

Table 8: Gender-specific Diagnosed Prevalent Cases of Von Willebrand Disease in the US (2018–2030)

Table 9: Age-specific Diagnosed Prevalent Cases of Von Willebrand Disease in the US (2018–2030)

Table 10: Type-specific Diagnosed Prevalent Cases of Von Willebrand Disease in the US (2018–2030)

Table 11: List of Marketed Drugs Analysis

Table 12: List of Marketed Drugs Analysis, continued..

Table 13: Vonvendi, Clinical Trial Description, 2021

Table 14: Wilate, Clinical Trial Description, 2021

Table 15: The United States Market Size of Von Willebrand Disease in USD Million (2018–2030)

Table 16: The US Market Size of Von Willebrand Disease by Therapies in USD Million (2018–2030)

List of Figures:

List of Figures

Figure 1: The structure of VWF

Figure 2: Biosynthesis and Function of von Willebrand Factor

Figure 3: Symptoms of Subtypes of Type 2

Figure 4: Biosynthesis and Function of von Willebrand Factor

Figure 5: Type 2 VWD Variants

Figure 6: Structure and function of pre-pro VWF

Figure 7: Pathophysiological Mechanisms and Classification of von Willebrand Disease

Figure 8: Initial hemostasis laboratory evaluation

Figure 9: Algorithm proposed for the diagnosis and classification of VWD

Figure 10: Treatment scheme for Von Willebrand Disease

Figure 11: Diagnosed Prevalent Cases of Von Willebrand Disease in the United States (2018–2030)

Figure 12: Gender-Specific Diagnosed Prevalent Cases of Von Willebrand Disease in the US (2018–2030)

Figure 13: Age-Specific Diagnosed Prevalent Cases of Von Willebrand Disease in the US (2018–2030)

Figure 14: Type-Specific Diagnosed Prevalent Cases of Von Willebrand Disease in the US (2018–2030)

Figure 15: Market Size of Von Willebrand Disease in the United States, USD Million (2018–2030)

Figure 16: Market Size of Von Willebrand Disease by Therapies in the US, USD Million (2018–2030)

Figure 17: Market Drivers

Figure 18: Market Barriers

Figure 19: Unmet Needs

Related Reports

Von Willebrand disease Market Insight, Epidemiology And Market Forecast - 2034

Von Willebrand disease Market report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends in 7MM.

Von Willebrand Disease - Market Insight, Epidemiology And Market Forecast - 2032

DelveInsight's Von Willebrand Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Von Willebrand Disease, historical and forecasted epidemiology as well as the Von Willebrand Disease market trends in 7MM.